SCHEMBL2333879

SCHEMBL2333879

O=C(N1CCc2cc(CN3CCC3)ccc2C1)C(F)(F)F

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.62
ESR2 Q92731 5/20 0.62
FAAH O00519 1/20 0.44
ABHD6 Q9BV23 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
PKM P14618 1/20 0.41
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
ACACB O00763 2/20 0.41
ROCK2 O75116 1/20 0.41
NAMPT P43490 1/20 0.41
CCR3 P51677 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3060013 0.96 ESR1 (0.61) ESR1ESR2FAAHABHD6CYP3A4
SCHEMBL13439632 0.80 KCNJ1 (0.48) ESR1ESR2ABHD6HPGDHSP90AA1
SCHEMBL22070855 0.79 ESR1 (0.68) ESR1ESR2ABHD6HDAC8HDAC6
SCHEMBL13650396 0.79 ESR1 (0.68) ESR1ESR2ABHD6HDAC8HDAC6
SCHEMBL565064 0.77 ESR1 (0.58) ESR1ESR2FAAHABHD6HDAC8
SCHEMBL8176145 0.77 ESR2 (1.00) ESR1ESR2ABHD6HDAC8HDAC6
SCHEMBL14677183 0.76 ESR2 (0.59) ESR1ESR2ABHD6HPGDCYP2C19
SCHEMBL25206226 0.76 ESR2 (0.76) ESR1ESR2ABHD6HDAC8HDAC6
SCHEMBL419896 0.76 ESR2 (0.72) ESR1ESR2ABHD6HDAC8HDAC6
SCHEMBL4179872 0.76 ESR2 (0.72) ESR1ESR2ABHD6HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP disclosed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
EP-2356101-A1 PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN Grünenthal GmbH (DE) 2011-08-17 EP disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed
WO-2010046109-A1 PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN Grünenthal GmbH (DE) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS ESR1 2373/4885ESR2 2631/4885FAAH 3492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.